Blog
JPM 2026: Why This Feels Like a Turning Point for Biotech and Pharma Leadership
Heading into JPM this year, the difference was immediately noticeable. After several years defined by caution and constraint, JPM 2026 felt like a turning point. The conversations our team had with CEOs, CMOs, Board Members and investors reflected a level of optimism and urgency we have not experienced since 2021. While no one is calling this a boom, there is genuine conviction ...


